Financial Performance - The company's operating revenue for the third quarter was RMB 499,511,815.43, representing a year-on-year increase of 55.01%[4] - Net profit attributable to shareholders for the third quarter was RMB 260,913,556.78, showing a significant year-on-year growth of 176.77%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached RMB 260,340,236.28, with a year-on-year increase of 195.97%[4] - The basic earnings per share for the third quarter was RMB 0.49, an increase of 88.46% compared to the same period last year[5] - The diluted earnings per share for the third quarter was RMB 0.49, with an increase of 88.46% compared to the same period last year[5] - The company reported a net profit attributable to shareholders for the year-to-date of 154.85%, driven by business growth and increased financial income[11] - Diluted earnings per share for the year-to-date increased by 76.12%, due to business growth and increased financial income[12] - Total revenue for the first three quarters of 2022 reached ¥1,276,392,981.45, a significant increase from ¥856,804,399.15 in the same period of 2021, representing a growth of approximately 49%[22] - Net profit attributable to shareholders of the parent company for the first three quarters of 2022 was ¥632,033,151.04, up from ¥248,006,161.31 in 2021, reflecting a growth of approximately 154%[24] - Basic earnings per share for the first three quarters of 2022 were ¥1.18, compared to ¥0.68 in the same period of 2021, marking an increase of about 74%[25] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was RMB 778,288,380.46, representing a year-on-year increase of 67.93%[4] - Cash flow from operating activities for the year-to-date increased by 67.93%, due to increased sales collections and interest income[11] - Cash inflow from operating activities in the first three quarters of 2022 was ¥2,085,281,684.08, compared to ¥1,422,490,961.55 in 2021, showing an increase of approximately 47%[28] - The total assets at the end of the reporting period amounted to RMB 10,079,078,937.04, reflecting an increase of 18.06% from the end of the previous year[5] - Current assets totaled approximately 5.72 billion RMB, slightly down from 5.81 billion RMB at the end of 2021, indicating a decrease of about 1.2%[18] - The company's cash and cash equivalents were reported at approximately 2.87 billion RMB, down from 4.15 billion RMB at the end of 2021, a decline of about 30.8%[17] - The total cash and cash equivalents at the end of the third quarter of 2022 were approximately 2.85 billion, down from 4.11 billion at the end of the same period in 2021[31] - The company reported a net increase in cash and cash equivalents of approximately -1.30 billion in the first three quarters of 2022, compared to an increase of 3.81 billion in the same period of 2021[31] Liabilities and Equity - The total liabilities increased to approximately 2.41 billion RMB from 1.39 billion RMB, representing a growth of about 73.5%[20] - The company's equity attributable to shareholders rose to approximately 7.66 billion RMB, compared to 7.14 billion RMB at the end of 2021, an increase of about 7.4%[20] Inventory and Investments - The company reported a significant increase in inventory, which rose to approximately 2.21 billion RMB from 700.59 million RMB, a growth of about 215.5%[18] - The long-term investments decreased slightly to approximately 23.66 million RMB from 25.29 million RMB, a decline of about 6.5%[18] - The company experienced a decrease in investment income from joint ventures and associates, reporting a loss of ¥1,632,476.09 in the first three quarters of 2022[23] Operational Highlights - The company has secured a strong order backlog of over 4.6 billion RMB, ensuring robust future revenue growth[16] - The company has implemented effective measures to ensure the smooth delivery of orders, which is expected to positively impact future performance[16] - The company is focusing on new product development and market expansion strategies to enhance its competitive position in the industry[16] Research and Development - Research and development expenses for the first three quarters of 2022 amounted to ¥50,053,890.87, up from ¥35,019,894.79 in 2021, indicating a growth of about 43%[22] Other Financial Metrics - The company reported a loss of RMB 4,880,000 from the valuation changes of trading financial assets during the year-to-date[6] - The company recognized government subsidies amounting to RMB 8,457,000 for the year-to-date, compared to RMB 2,361,000 in the same period last year[7] - The company recorded a net loss of -3,089,926.69 from fair value changes in financial assets and liabilities[10] - The company has not defined any non-recurring gains and losses as recurring gains and losses[10] - Other comprehensive income after tax for the first three quarters of 2022 was ¥35,188,864.58, compared to -¥1,441,837.91 in 2021, indicating a positive turnaround[24]
昭衍新药(06127) - 2022 Q3 - 季度财报